| Literature DB >> 26490350 |
Brajendra K Singh1, Edwin Michael2.
Abstract
BACKGROUND: Mathematical models of parasite transmission can help integrate a large body of information into a consistent framework, which can then be used for gaining mechanistic insights and making predictions. However, uncertainty, spatial variability and complexity, can hamper the use of such models for decision making in parasite management programs.Entities:
Mesh:
Year: 2015 PMID: 26490350 PMCID: PMC4618871 DOI: 10.1186/s13071-015-1132-7
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Description of baseline survey data. The study sites are given with the baseline sample size and microfilariae (mf) prevalence (%), blood volumes collected during the survey to test for mf positivity, annual biting rate (ABR) of vector mosquitoes, dominant vector species and drug regimen used for simulating the chemotherapeutic interventions by mass drug administration (MDA) without/with vector control (VC)
| Study villages | Mf Sample size | Blood volume | cMf (%) | dBaseline ABR | CFA sample size | CFA (%) | Mosquito species (genus) | aDrug regimen |
bDrug’s efficacies ( | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| Peneng | 63 | 1000 | 66.67 | 8194 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Albulum | 50 | 1000 | 80 | 42328 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Yauatong | 131 | 1000 | 92.37 | 37052 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Nanaha | 211 | 1000 | 54.98 | 11611 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Ngahmbule | 346 | 1000 | 51.16 | 4346 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Tawalani | 367 | 100 | 35.72 | 12850 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| eJaribuni | 1007 | 100 | 25.35 | 15677 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| Tingrela | 699 | 20 | 63.89 | 4156 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| Chiconi | 245 | 20 | 58.90 | 10586 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| eMasaika | 848 | 100 | 28.61 | 6184 | 837 | 52.2 |
| IVM + ALB | (35, 99, 9) | [ |
| eKirare | 919 | 100 | 28.18 | 2090 | 90 | 53.3 |
| IVM + ALB | (35, 99, 9) | [ |
| eAlebtong | 739 | 100 | 33.47 | 58292 | 890 | 29.1 |
| IVM + ALB | (35, 99, 9) | [ |
| eLwala | 572 | 100 | 21.05 | 16341 | 896 | 18.3 |
| IVM + ALB | (35, 99, 9) | [ |
| eObalanga | 799 | 100 | 34.62 | 4587 | 900 | 30.1 |
| IVM + ALB | (35, 99, 9) | [ |
| eKingwede | 825 | 100 | 3.07 | 1548 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| eMao | 546 | 100 | 27.8 | 25439 | - | - |
| IVM + ALB | (35, 99, 9) | [ |
| eMambrui | 787 | 100 | 24.99 | 4964 | - | - | Cx. | IVM + ALB | (35, 99, 9) | [ |
| Pondicherry | 1549 | 20 | 34.74 | 88500 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Calcutta | 861 | 20 | 26.72 | 115942 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Vettavallam | 7976 | 20 | 22.83 | 100375 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Pakistan | 1443 | 20 | 31.49 | 1607 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
| Jakarta | 922 | 20 | 12.27 | 223000 | - | - |
| DEC + ALB | (55, 95, 6) | [ |
An.: Anopheles mosquitoes; Cx.: Culex mosquitoes; Drug’s efficacies (ω,ε, T ): (instantaneous kill rate (%) for adult worms, instantaneous kill rate (%) for mf, drug’s efficacy period in months); mf (%): mf prevalence in percentages calculated from the number of mf-positive samples out of the total individuals sampled (sample size) in a study site; DEC: diethylcarbamazine citrate; IVM: Ivermectin; ALB: Albendazole.
aThe combination drug regimens used for MDA simulations in each site areas are as recommended for each site region by the WHO [95, 96].
bDrug efficacy values are taken from [3].
cAll mf prevalence values were standardized to reflect sampling of 1 ml blood volumes using a transformation factor of 1.95 and 1.15 respectively for values originally estimated using 20 or 100 μl blood volumes [49].
dBaseline ABR are used to obtain the monthly biting rate (MBR = ABR/12), which is used as inputs into the LF models described in the text. The symbol (−) indicates that the baseline CFA data are either not available or available but not broken by age-groups.
eThese sites have mixed vector species: here they are represented by the dominant vector species.
Fig. 1Observed and fitted microfilariae (mf) age-prevalences of lymphatic filariasis (LF) for twenty-two study sites. The cyan lines denote the SIR BM model fits to observed baseline mf prevalences in different age-groups (red squares with binomial error-bars) from each of the 22 study sites. The age-groups in the figures are represented by the mid-point of the groups studied in each community. Study sites and details of survey data are described in Table 1. All mf prevalence values were standardized to reflect sampling of 1 ml blood volumes using a transformation factor of 1.95 and 1.15 respectively for values originally estimated using 20 or 100 μL blood volumes [49]
Fig. 2Prior and posterior model parameter distributions for the data from each site. Results are shown for nine parameters (labels on top of each column), which were identified by a formal Kolmogorov-Smirnov (KS) two-sample test, to be significantly different from their flat priors across the majority of the study sites. Distribution plots for a parameter shown in gray denotes that the parameter did not differ significantly from the assigned flat priors for a study site
Model-estimated mf and L3 breakpoint values for achieving the successful interruption of LF transmission in each of the study sites investigated. Breakpoints are listed in terms of mf and L3 prevalences (%) at 95 % probability of elimination for two situations: 1) at the prevailing vector biting rates (ie., at the observed ABRs) and 2) at the threshold biting rate (TBR) at or below which LF transmission process cannot sustain itself regardless of the level of the infection in human hosts (see text). The first set of the threshold values (at study-specific ABR) is used in modeling the impact of mass drug administration (MDA) alone, while the 2nd set (ie., mf breakpoint values estimated at TBR) is applied for modeling the impact when MDA is supplemented by vector control (VC)
| Study villages | Mean TBR | Mf bpts at ABR | L3 bpts at ABR | Mf bpts at TBR | L3 bpts at TBR |
|---|---|---|---|---|---|
| Peneng | 5635 | 0.035429 | 0.001116 | 0.435501 | 0.021181 |
| Albulum | 11025 | 0.004885 | 0.000028 | 0.094346 | 0.010902 |
| Yauatong | 6185 | 0.002985 | 0.000021 | 0.066789 | 0.008942 |
| Nanaha | 9309 | 0.066568 | 0.001827 | 0.919664 | 0.022993 |
| Ngahmbule | 3365 | 0.058476 | 0.001996 | 0.45293 | 0.02599 |
| Tawalani | 10503 | 0.085207 | 0.001871 | 1.07946 | 0.02192 |
| Jaribuni | 13451 | 0.077864 | 0.002772 | 1.112716 | 0.022068 |
| Tingrela | 3310 | 0.042786 | 0.001659 | 0.559656 | 0.02453 |
| Chiconi | 7315 | 0.033768 | 0.000781 | 0.677308 | 0.018855 |
| Masaika | 5390 | 0.053393 | 0.002915 | 0.451975 | 0.451975 |
| Kirare | 1016 | 0.018212 | 0.000805 | 0.721577 | 0.061739 |
| Alebtong | 18703 | 0.007344 | 0.000088 | 0.22969 | 0.014427 |
| Lwala | 6201 | 0.015075 | 0.000217 | 0.259451 | 0.021331 |
| Obalanga | 1600 | 0.010066 | 0.000349 | 0.907932 | 0.047025 |
| Kingwede | 1363 | 0.022236 | 0.0021 | 0.089295 | 0.014983 |
| Mao | 20062 | 0.019268 | 0.002728 | 0.384838 | 0.038674 |
| Mambrui | 4445 | 0.075622 | 0.007421 | 0.885393 | 0.065253 |
| Pondicherry | 40223 | 0.000476 | 0.000025 | 0.041653 | 0.007822 |
| Calcutta | 86719 | 0.017295 | 0.001197 | 0.178704 | 0.019703 |
| Vettavallam | 66478 | 0.002706 | 0.000147 | 0.110904 | 0.017511 |
| Pakistan | 1311 | 0.034034 | 0.00316 | 0.659793 | 0.047162 |
| Jakarta | 88494 | 0.000171 | 0.000015 | 0.028576 | 0.00373 |
|
a
| <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
|
a
| <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
a P-values are from results of Kruskal-Wallis rank sum tests for assessing differences in TBRs, L3 and mf breakpoints among sites within each of the Anopheline (An) and Culicine (Cx) LF settings
Fig. 3Observed and fitted circulating filarial antigen (CFA) and microfilariae (mf) age-prevalences of lymphatic filariasis (LF) for five study sites. The model fits (cyan lines) to the observed baseline CFA and mf age-data (red squares with binomial error-bars) were obtained using a bivariate binomial likelihood function as derived and discussed in [44]. Note that both CFA and mf data were available only for five study sites
The production and decay/clearance rate parameters for the Circulating Filarial Antigen (CFA) of LF
| Study villages | Average | Median | 2.5th | 97.5th |
|---|---|---|---|---|
| Production rate | ||||
| Masaika | 5.69 | 6.61 | 4.47 | 6.61 |
| Kirare | 6.49 | 6.57 | 4.89 | 6.66 |
| Alebtong | 3.81 | 3.85 | 2.51 | 4.61 |
| Lwala | 5.50 | 5.73 | 2.97 | 6.77 |
| Obalanga | 7.02 | 7.09 | 6.84 | 7.16 |
| Decay rate | ||||
| Masaika | 0.028 | 0.029 | 0.027 | 0.029 |
| Kirare | 0.015 | 0.015 | 0.015 | 0.024 |
| Alebtong | 0.045 | 0.045 | 0.037 | 0.05 |
| Lwala | 0.043 | 0.044 | 0.031 | 0.047 |
| Obalanga | 0.042 | 0.042 | 0.032 | 0.049 |
| Survival period | ||||
| Masaika | 35.48 | 34.78 | 34.78 | 37.67 |
| Kirare | 65.28 | 66.51 | 42.06 | 67.00 |
| Alebtong | 22.49 | 22.34 | 20.29 | 26.81 |
| Lwala | 23.63 | 22.87 | 21.40 | 31.76 |
| Obalanga | 24.36 | 23.84 | 20.56 | 31.68 |
These values were obtained from the joint model fits to CFA and mf age-profiles data from five African LF endemic communities. The production and decay rates are, respectively, given in units of per worm per month and per month, while the survival period (ie., the inverse of the decay rate) is in the unit of month
Model-estimated CFA (at community-level as well as in 6–7 years age-cohort), and mf breakpoint values for achieving the successful interruption of LF transmission in each of the five study sites that have both CFA and mf baseline age data. As in Table 2, breakpoints are listed in terms of prevalences (%) for CFA and mf at 95 % probability of elimination for two situations: 1) at the prevailing vector biting rates (ien, at the observed ABRs); and 2) at the threshold biting rates (TBRs) at or below which LF transmission process cannot sustain itself regardless of the level of the infection in human hosts
| Study villages | Mean TBR | 95 %-EP Breakpoint values at ABRs | 95 %-EP Breakpoint values at ABRs | ||||
|---|---|---|---|---|---|---|---|
| CFA bpts | CFA6to7 bpts | Mf bpts | CFA bpts | CFA6to7 bpts | Mf bpts | ||
| Masaika | 731 | 0.067185 | 0.004926 | 0.012826 | 0.146865 | 0.047919 | 0.136688 |
| Kirare | 497 | 0.089053 | 0.014116 | 0.026547 | 0.204496 | 0.056584 | 0.116281 |
| Alebtong | 6653 | 0.049452 | 0.002917 | 0.006474 | 0.112308 | 0.024612 | 0.05454 |
| Lwala | 3729 | 0.060131 | 0.005485 | 0.014214 | 0.12293 | 0.043296 | 0.090148 |
| Obalanga | 867 | 0.071218 | 0.010358 | 0.019089 | 0.150288 | 0.060039 | 0.127721 |
EP: elimination probability; bpts: breakpoints; CFA6to7: Circulating Filarial Antigen in 6 to 7 years old.
Fig. 4Impact of annual mass drug administration (MDA) alone at 80 % coverage on the model-predicted community-level microfilariae (mf) prevalences of lymphatic filariasis (LF) for each study site. Note that the prevalence values on the y-axis are on a logarithmic scale. Simulations at MDA coverage of 80 % were carried out for three decades using the best-fit parameter vectors obtained by model-fitting to the baseline mf age-prevalence data in each site (cf. Fig. 1). The MDA start time is indicated by 0 on the x-axis. The horizontal dashed line in each plot represents the model-derived extinction threshold signifying 95 % probability of elimination (site-specific numerical values are provided in Table 2), whereas the vertical dashed line denotes the time-point since the start of mass treatment at which the modelled community-level mf prevalences had reduced/crossed below their respective 95 %-EP threshold values for all the best parameter vectors. Note that in these simulations, models were run forward for each site without the effect of drug treatments after the time-points indicated by the vertical lines were crossed
Fig. 5Impact of annual mass drug administration (MDA) at 80 % coverage with supplemental vector control (VC) on the model-predicted community-level microfilariae (mf) prevalence of lymphatic filariasis (LF) for each study site. The supplemental VC was implemented at the population-level coverage of 80 %, and its effect was continued throughout the model simulation period, ie. even beyond the MDA stopping time-point indicated by the vertical lines. All other details as described in Fig. 4
Model-predicted required mean number of years of mass treatments for different intervention scenarios for achieving the successful interruption of LF transmission in each of the study sites investigated. The required years of mass treatments were determined by evaluating whether as a result of intervention, the model-predicted community-level mf prevalence had reduced below the mf elimination threshold signifying 95 % probability of elimination for the four scenarios: 1) intervention by annual mass drug administration (MDA) alone; 2) annual MDA with supplemental vector control (VC); 3) biennial MDA alone; and 4) biennial MDA with supplemental VC. VC, where applicable, was implemented at the community coverage of 80 %. The results in this table are shown for three MDA coverages: 60, 80 and 100 %
| Annual MDA alone | Annual MDA + VC | Biennial MDA alone | Biennial MDA + VC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Study villages | 60 % | a80% | 100 % | 60 % | a80% | 100 % | 60 % | a80% | 100 % | 60 % | a80% | 100 % |
| Peneng | 17 | 12 | 9 | 10 | 7 | 6 | 9 | 6 | 5 | 5 | 4 | 3 |
| Albulum | 26 | 20 | 15 | 17 | 12 | 9 | 15 | 11 | 10 | 9 | 7 | 6 |
| Yauatong | 28 | 23 | 18 | 19 | 14 | 11 | 18 | 14 | 13 | 10 | 8 | 7 |
| Nanaha | 15 | 10 | 8 | 8 | 6 | 4 | 8 | 5 | 5 | 4 | 3 | 2 |
| Ngahmbule | 15 | 10 | 8 | 9 | 7 | 5 | 8 | 5 | 4 | 5 | 3 | 2 |
| Tawalani | 18 | 13 | 10 | 9 | 7 | 5 | 10 | 7 | 4 | 5 | 3 | 1 |
| Jaribuni | 17 | 13 | 9 | 8 | 6 | 4 | 9 | 6 | 4 | 4 | 2 | 1 |
| Tringela | 20 | 14 | 11 | 10 | 8 | 6 | 11 | 7 | 4 | 5 | 3 | 1 |
| Chiconi | 22 | 16 | 13 | 12 | 9 | 7 | 12 | 9 | 5 | 6 | 4 | 2 |
| Masaika | 18 | 13 | 10 | 10 | 8 | 6 | 10 | 7 | 4 | 5 | 3 | 1 |
| Kirare | 21 | 16 | 12 | 8 | 6 | 4 | 12 | 8 | 4 | 4 | 2 | 1 |
| Alebtong | 25 | 19 | 14 | 12 | 9 | 7 | 15 | 10 | 6 | 7 | 4 | 2 |
| Lwala | 20 | 14 | 11 | 9 | 7 | 5 | 11 | 8 | 4 | 5 | 3 | 1 |
| Obalanga | 22 | 16 | 13 | 7 | 5 | 4 | 13 | 9 | 5 | 3 | 2 | 1 |
| Kingwede | 16 | 11 | 8 | 10 | 8 | 6 | 8 | 6 | 3 | 5 | 3 | 1 |
| Mao | 21 | 16 | 12 | 11 | 8 | 6 | 12 | 8 | 5 | 6 | 4 | 1 |
| Mambrui | 17 | 12 | 9 | 8 | 6 | 4 | 9 | 6 | 4 | 4 | 2 | 1 |
| Pakistan | 15 | 10 | 8 | 8 | 6 | 4 | 8 | 5 | 5 | 4 | 3 | 2 |
| Pondicherry | 24 | 18 | 13 | 15 | 11 | 8 | 13 | 9 | 8 | 8 | 6 | 5 |
| Calcutta | 15 | 11 | 8 | 9 | 7 | 5 | 8 | 5 | 4 | 5 | 3 | 2 |
| Vettavallam | 19 | 13 | 10 | 11 | 8 | 6 | 10 | 7 | 6 | 6 | 4 | 3 |
| Jakarta | 25 | 21 | 16 | 17 | 13 | 9 | 16 | 12 | 9 | 9 | 6 | 5 |
|
bTotal variance( | 3.52 | 2.66 | 1.37 | 1.15 | ||||||||
|
bTotal variance( | 1.52 | 1.20 | 0.51 | 0.49 | ||||||||
aThe required years of mass treatments at the MDA coverage of 80 %, without and with vector control, significantly differed within Anopheline and Culicine settings (Kruskal-Wallis test p-values <0.0001)
bTotal variance denotes the overall variance in the required years of mass treatments estimated from all sites within each of the Anopheline and Culicine settings. Data are provided for 80 % coverage for annual and biennial MDAs without and with vector control at 80 % coverage
Fig. 6Impact of annual mass drug administration (MDA) alone at 80 % coverage on the model-predicted community-level microfilariae (mf), third-stage larvae (L3) and circulating filarial antigen (CFA) prevalences of lymphatic filariasis (LF) for the five study sites that provided both mf and CFA baseline age data. The intervention simulations were carried out with the best model parameters obtained by joint fitting to both CFA and mf baseline data. The horizontal dashed line in each plot represents the model-derived extinction threshold signifying 95 % probability of elimination for the respective state variables, whereas the vertical dashed line denotes the time-point since the start of mass treatment at which the modelled prevalences had reduced/crossed below their respective 95 %-EP threshold values for all the best parameter vectors in the case of mf and L3 prevalences; beyond this time-point model runs were carried out without the effect of drug treatments as in Figs. 4 and 5. Note that for CFA, thresholds were crossed only much after 30 years (data not shown)
Probability of LF extinction at the WHO threshold of 1 % mf prevalence. See text for details of estimation
| Study villages | Probability of extinction at ABR | Probability of extinction at TBR |
|---|---|---|
| Peneng | 7.75 | 89.59 |
| Albulum | 0.43 | 40.86 |
| Yauatong | 0.54 | 36.93 |
| Nanaha | 16.67 | 95.24 |
| Ngahmbule | 14.55 | 92.99 |
| Tawalani | 16.3 | 96.3 |
| Jaribuni | 21.79 | 96.15 |
| Tingrela | 15.38 | 79.49 |
| Chiconi | 7.94 | 93.33 |
| Masaika | 23.6 | 89.89 |
| Kirare | 16.71 | 36.86 |
| Alebtong | 0.95 | 71.43 |
| Lwala | 0 | 74.49 |
| Obalanga | 0 | 78.89 |
| Kingwede | 3.67 | 48.93 |
| Mao | 4.44 | 90 |
| Mambrui | 31.31 | 95.96 |
| Pondicherry | 6.9 | 34.48 |
| Calcutta | 2.73 | 66.36 |
| Vettavallam | 0 | 55.77 |
| Pakistan | 9.45 | 93.44 |
| Jakarta | 18.98 | 24.82 |
Fig. 7Risk of recrudescence of LF in communities as a result of the stopping of mass treatment following the WHO-recommended threshold of 1 % community-level microfilariae (mf) prevalence. Results shown in gray are for the LF intervention scenario when mass treatments (annual MDAs at 80 % coverage with no supplemental vector control) were stopped after the overall modelled mf prevalences crossed below the WHO-recommended threshold of 1 % (shown by solid horizontal line) in each site, whereas in the case of green curves, mass treatments were stopped after the modelled prevalences had reduced below the model-derived 95 %-EP thresholds (depicted by dashed horizontal line, for values cf. Table 2) in a site. Note that MDA stopping times for these thresholds varied within each site, with the vertical dotted line denoting the time-point when all model runs in a site had crossed the 95 %-EP threshold estimated for that site. Note that when modelled prevalences cross the 95 % EP in a site, all further simulated prevalences decayed steadily to the 0 state attractor, as predicted by theory [7]. The recrudescence probabilities (calculated as the percentage of the total model runs in which the mf prevalence rose above the 1 % threshold by the end of the simulation period) are provided in parentheses beside the names of the study sites
Fig. 8Risk of recrudescence of LF in communities as a result of the stopping of mass treatment following the WHO-recommended threshold of 1 % community-level microfilariae (mf) prevalence. These results are shown for the biennial MDA with supplemental vector control. The coverage levels in this set of intervention runs, for both MDA and VC, were kept at 80 %. All other details, including color codes, are as given in Fig. 7